Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D06ZWG
|
|||
| Former ID |
DCL000709
|
|||
| Drug Name |
AVE-5997EF
|
|||
| Synonyms |
UNII-7E6G867INX; 7E6G867INX; SCHEMBL5667413; L001680; 1-p-Tolyl-3-(4-(4-(6-trifluoromethylbenzo(b)thien-3-yl)piperazin-1-yl)butyl)urea; Urea, N-(4-methylphenyl)-N'-(4-(4-(6-(trifluoromethyl)benzo(b)thien-3-yl)-1-piperazinyl)butyl)-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 1 | [1] | |
| Schizophrenia [ICD-11: 6A20] | Terminated | [2] | ||
| Company |
Sanofi-Aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H29F3N4OS
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)NC(=O)NCCCCN2CCN(CC2)C3=CSC4=C3C=CC(=C4)C(F)(F)F
|
|||
| InChI |
1S/C25H29F3N4OS/c1-18-4-7-20(8-5-18)30-24(33)29-10-2-3-11-31-12-14-32(15-13-31)22-17-34-23-16-19(25(26,27)28)6-9-21(22)23/h4-9,16-17H,2-3,10-15H2,1H3,(H2,29,30,33)
|
|||
| InChIKey |
XVFIYMFVLGFALY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 452917-21-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dopamine D3 receptor (D3R) | Target Info | Antagonist | [2] |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Dopaminergic synapse | ||||
| Reactome | Dopamine receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| Nicotine Activity on Dopaminergic Neurons | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018413) | |||
| REF 2 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.